Sanofi has presented new data on the potential of its Glargine insulin ('toujeo') drugof the American Diabetes Association that has been held in Washington (United States).
With regard to the first of these drugs, the new data has shown that, with a control of similar blood glucose, there is a significantly lower risk of suffering documented hypoglycemic episodes after changing to 'toujeo', with 57 percent less thanprobability.
A finding that goes online and is consistent with previous data in adults with type 2 diabetes and demonstrates the clinical benefit "in real life compared to other basal insulins, and how this translates into a global cost savings."
With regard to 'Suliqua', its use reduced average glycemia (HBA1C) between 1.09 and 2.41 percent after 30 weeks in adults with type 2 diabetes and that had been previously treated with a daily dosebetween 15 and 40 units of basal insulin, which also showed that all subgroups reached an average HBA1C of less than 7 percent at the end of the study period.
"Reducing high levels of HBA1C constitutes an important therapeutic objective in people suffering from diabetes," said Riccardo Perfetti, a global medical person responsible for the Sanofi Diabetes Division.
